26
|
Barassi G, Younes A, Di Iulio A, Guerri S, Guglielmi V, Della Rovere F, Supplizi M, Di Iorio A. Fibromyalgia and therapeutic integration: role of quantum medicine. J BIOL REG HOMEOS AG 2020; 34:1193-1197. [PMID: 32627513 DOI: 10.23812/20-165-l-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
27
|
Younes A, Ali JS, Nur MT, Duda A, Wang J, Samson J, Kawamura A, Francesconi L, Alexandratos S, Drain CM. Pistachio shells as remediating agents for uranium in contaminated industrial seawater. JOURNAL OF ENVIRONMENTAL RADIOACTIVITY 2020; 217:106209. [PMID: 32217241 DOI: 10.1016/j.jenvrad.2020.106209] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 02/04/2020] [Accepted: 02/15/2020] [Indexed: 06/10/2023]
Abstract
Waterways have histories of being contaminated by heavy and/or radioactive metals produced by industrial processes. Natural radioisotopes of uranium (238U, 235U and 234U), long-lived radiometals, are widespread in the environment as a result of both naturally occurring processes and anthropogenic processes. Uranium is considered a major threat to humans. Previous research has focused on using inorganic materials (e.g. ion-exchangers, extractants, nanoporous sorbents) to remove such metal. However, there has been a rise in using biodegradable, recyclable, and organic biological wastes to remove heavy toxic metals from aqueous solutions. The purpose of this study is to identify pistachio shells as good candidates for the removal of uranyl from aqueous solutions. The influences of pH, contact time, temperature, and initial uranyl concentration on uranyl uptake were investigated. The influence of pH was observed to be variable, with relatively high uptake occurring at pH 4 and at slightly alkaline pH values. Uptake increased as a function of contact time, temperature, and initial uranyl concentration. The mechanism followed pseudo-second-order and intraparticle kinetics models, and the shell was demonstrated to be a Freundlich isotherm. The shells were successfully demonstrated to be viable adsorbents for uranium in seawater samples, with obtained trends similar to those achieved in the batch studies.
Collapse
|
28
|
Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D. Evaluation of Inorganic Ion Exchange Materials for Purification of 225Ac from Thorium and Radium Radioisotopes. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Menon H, Ramapriyan R, Verma V, Barsoumian H, Cushman T, Younes A, Chen D, Cortez M, Erasmus J, de Groot P, Carter B, Hong D, Diab A, Glitza I, Heymach J, Tang C, Nguyen Q, Chun S, Welsh J. Influence of Low-Dose Radiation on Abscopal Responses in NSCLC Metastases: Analysis of Three Prospective Institutional Trials. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Bhupathiraju NVSDK, Younes A, Cao M, Ali J, Cicek HT, Tully KM, Ponnala S, Babich JW, Deri MA, Lewis JS, Francesconi LC, Drain CM. Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO. Org Biomol Chem 2019; 17:6866-6871. [PMID: 31268109 PMCID: PMC6640124 DOI: 10.1039/c9ob01068h] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(iv) and, more importantly, the radioisotope 89Zr for use in radiolabeling antibodies for positron emission tomography (PET) imaging. Previous studies of 89Zr-HOPO-trastuzumab in mice showed low background, good tumor to organ contrast, and very low bone uptake which show p-SCN-Bn-HOPO to be an important next-generation bifunctional chelator for radioimmunoPET imaging with 89Zr. However, the reported synthesis of p-SCN-Bn-HOPO involves nine steps and multiple HPLC purifications with an overall yield of about 1.4%. Herein we report an improved and efficient synthesis of p-SCN-Bn-HOPO in four steps with 14.3% overall yield which will improve its availability for further biological studies and wider application in PET imaging. The new synthetic route also allows variation in linker length and chemistries which may be helpful in modifying in vivo clearance behaviors of future agents.
Collapse
|
31
|
Hatcher J, Younes A, Cicek H, Burton-Pye B, Fitzsimmons J, Cutler C, Francesconi L. The application of polyoxometalates to thorium debulking studies for actinium-225 production. Nucl Med Biol 2019. [DOI: 10.1016/s0969-8051(19)30245-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Okosun J, Bödör C, Batlevi C, Nagy N, Michot J, Schneider T, Alizadeh H, Simon Z, Vose J, Younes A, Ribrag V, Fitzgibbon J, Yang J, Agarwal S, Newberry K, Michaud N. EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
33
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
34
|
Batlevi C, Palomba M, Park J, Mead E, Santomasso B, Riviere I, Wang X, Senechal B, Furman R, Yang J, Kane P, Hall M, Bernal Y, Lund N, Diamonte C, Pineda J, Halton E, Moskowitz C, Younes A, Sadelain M, Brentjens R. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION. Hematol Oncol 2019. [DOI: 10.1002/hon.124_2629] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
35
|
Sermer D, Bobillo S, Seshan V, Dogan A, Younes A. CLINICAL SIGNIFICANCE AND OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) HARBORING EXTRA COPIES [EC] AND/OR TRANSLOCATIONS [TL] OF MYC, BCL2, AND BCL6. Hematol Oncol 2019. [DOI: 10.1002/hon.12_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
36
|
Balasubramanian S, Wang S, Major C, Hodkinson B, Schaffer M, Sehn L, Johnson P, Zinzani P, Carey J, Liu G, Loefgren C, Shreeve M, Sun S, Zhuang S, Vermeulen J, Staudt L, Younes A, Wilson W. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
37
|
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Straus D, Boccomini C, Tucci A, Zelenetz A, Seshan V, Luminari S, Marcheselli L, Federico M, Younes A. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.109_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
38
|
Bobillo S, Joffe E, Lavery J, Noy A, Palomba L, Straus D, Kumar A, Batlevi C, Horwitz S, Moskowitz A, Hamlin P, Zelenetz A, Matasar M, von Keudell G, Sermer D, Yahalom J, Dogan A, Seshan V, Younes A. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB-ERA. Hematol Oncol 2019. [DOI: 10.1002/hon.60_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
39
|
Younes A, Batlevi C, Cohen J, Kelly K, Landsburg D, Patel K, Phillips T, Smith S, Westin J, Ma A, Grayson D, Barta S. DOSE FINDING STUDY TO ASSESS SAFETY, PK AND EFFICACY OF FIMEPINOSTAT (CUDC-907) WITH VENETOCLAX OR RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
40
|
Rajeeve S, Bobillo S, Zelenetz A, Straus D, Palomba M, Noy A, Horwitz S, Moskowitz A, Hamlin P, Matasar M, Kumar A, Batlevi C, von Keudell G, Yahalom J, Dogan A, Drill E, Younes A, Joffe E. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP-LIKE REGIMENS. Hematol Oncol 2019. [DOI: 10.1002/hon.74_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
41
|
Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D. Evaluation of Inorganic Ion Exchange Materials for Purification of 225Ac from Thorium and Radium Radioisotopes. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Younes A, Panov AI. Toward Faster Reinforcement Learning for Robotics: Using Gaussian Processes. ARTIF INTELL 2019. [DOI: 10.1007/978-3-030-33274-7_11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Younes A, Creff G, Beccia MR, Moisy P, Roques J, Aupiais J, Hennig C, Solari PL, Den Auwer C, Vidaud C. Is hydroxypyridonate 3,4,3-LI(1,2-HOPO) a good competitor of fetuin for uranyl metabolism? Metallomics 2019; 11:496-507. [DOI: 10.1039/c8mt00272j] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Identification of stable HOPO–UO22+–fetuin ternary complexes after a chromatographic separation process.
Collapse
|
44
|
Neuschwander A, Job A, Younes A, Mignon A, Delgoulet C, Cabon P, Mantz J, Tesniere A. Impact of sleep deprivation on anaesthesia residents' non-technical skills: a pilot simulation-based prospective randomized trial. Br J Anaesth 2018; 119:125-131. [PMID: 28974071 DOI: 10.1093/bja/aex155] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2017] [Indexed: 11/13/2022] Open
Abstract
Background Sleep deprivation is common in anaesthesia residents, but its impact on performance remains uncertain. Non-technical skills (team working, situation awareness, decision making, and task management) are key components of quality of care in anaesthesia, particularly in crisis situations occurring in the operating room. The impact of sleep deprivation on non-technical skills is unknown. We tested the hypothesis that in anaesthesia residents sleep deprivation is associated with impaired non-technical skills. Methods Twenty anaesthesia residents were randomly allocated to undergo a simulation session after a night shift [sleep-deprived (SLD) group, n =10] or after a night of rest [rested (R) group, n =10] from January to March 2015. The simulated scenario was a situation of crisis management in the operating room. The primary end point was a composite score of anaesthetists' non-technical skills (ANTS) assessed by two blinded evaluators. Results Non-technical skills were significantly impaired in the SLD group [ANTS score 12.2 (interquartile range 10.5-13)] compared with the R group [14.5 (14-15), P <0.02]. This difference was mainly accounted for by a difference in the team working item. On the day of simulation, the SLD group showed increased sleepiness and decreased confidence in anaesthesia skills. Conclusions In this randomized pilot trial, sleep deprivation was associated with impaired non-technical skills of anaesthesia residents in a simulated anaesthesia intraoperative crisis scenario. Trial registration NCT02622217.
Collapse
|
45
|
Barsoumian H, Cushman T, Caetano M, Cadena A, Younes A, Tang C, Simon G, Cortez M, Welsh J. Low Dose Radiation Improves Anti-Tumor Responses in a Phase 2 Prospective Trial of Concurrent or Sequential Stereotactic Radiation and Ipilimumab in Patients with Metastatic Lesions. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Younes A, Alliot C, Mokili M, Montavon G. Is Polonium-210 a Good Indicator for Anthropogenic Radioactivity? Cancer Biother Radiopharm 2018; 33:356-360. [PMID: 30088970 DOI: 10.1089/cbr.2018.2496] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Anthropogenic radioactivity generated by nuclear or chemical events results in the liberation of quadrillions of Becquerel and tons of materials to the environment. These events include nuclear accidents, nuclear weapon experiments, and high levels of generated radioactive and chemical waste. 210Po is a high-energy α emitter that presents in the environment at extremely low concentration. It is considered as one of the highly toxic elements and is estimated to contribute about 7% of the total effective dose equivalent to humans from ingested natural internal radiation. The assessment of 210Po activity/concentration in the environment could be used as an indicator of the level of anthropogenic radioactivity. The 210Po concentration present in the most frequently sold cigarette produced in Lebanon was assayed using α spectrometry after a radiochemical separation and spontaneous deposition of Po on a copper disk. Although the geographical nature of Lebanese land is an extension of Syrian territory, the polonium activity concentration obtained is 8.8 times higher and attributable to the excessive use of phosphate fertilizers in agriculture. The individual committed effective dose was estimated to be equal to 219 ± 17 μSv/year of cigarette smoking.
Collapse
|
47
|
|
48
|
Abstract
CD30 and CD40 are members of the tumor necrosis factor (TNF) receptor family. These two receptors have pleiotropic biologic functions including induction of apoptosis and enhancing cell survival. This review will discuss the pattern of expression of these receptors in malignant lymphoid disorders and their prospective ligands. Understanding issues related to these two ligands and their receptors in lymphoid malignancies may help to improve the classification of these diseases and could open the doors for new treatment strategies.
Collapse
|
49
|
Gopal AK, Fanale MA, Moskowitz CH, Shustov AR, Mitra S, Ye W, Younes A, Moskowitz AJ. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma. Ann Oncol 2018; 28:1057-1063. [PMID: 28327905 DOI: 10.1093/annonc/mdx028] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background The phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib has been shown to block downstream intracellular signaling, reduce the production of prosurvival chemokines and induce apoptosis in classical Hodgkin lymphoma (HL) cell lines. It has also been shown to inhibit regulatory T cells and myeloid-derived suppressor cells in other tumor models. We hypothesized that inhibiting PI3Kδ would have both direct and indirect antitumor effects by directly targeting the malignant cells as well as modulating the inflammatory microenvironment. We tested this hypothesis in a phase II study. Patients and methods We enrolled 25 patients with relapsed/refractory HL with a median age of 42 years and who had previously received a median of five therapies including 18 (72%) with failed autologous stem cell transplant, 23 (92%) with failed brentuximab vedotin, and 11 (44%) with prior radiation therapy. Idelalisib was administered at 150 mg two times daily; an increase to 300 mg two times daily was permitted at the time of disease progression. Results The overall response rate to idelalisib therapy was 20% (95% confidence interval: 6.8%, 40.7%) with a median time to response of 2.0 months. Seventeen patients (68%) experienced reduction in target lesions with one complete remission and four partial remissions. The median duration of response was 8.4 months and median progression-free survival was 2.3 months. The most common grade ≥3 adverse event was elevation of alanine aminotransferase (two patients, 8%). Diarrhea/colitis was seen in three patients and was grade 1-2. There was one adverse event leading to death (hypoxia). Conclusions Idelalisib was tolerable and had modest single-agent activity in heavily pretreated patients with HL. Rational combinations with other novel agents may improve response rate and duration of response. Clinical trial registration ClinicalTrials.gov # NCT01393106.
Collapse
|
50
|
Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa A, D Ovidio C, Younes A, Gallenga CE, Conti P. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37. J BIOL REG HOMEOS AG 2018; 32:195-198. [PMID: 29684996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
It has been observed that acute stress causes the activation of TH1 cells, while TH2 cells regulate and act on chronic inflammation. Fibromyalgia (FM) is a chronic, idiopathic disorder which affects about twelve million people in the United States. FM is characterized by chronic widespread pain, fatigue, aching, joint stiffness, depression, cognitive dysfunction and non-restorative sleep. The mechanism of induction of muscle pain and inflammation is not yet clear. In FM there is an increase in reactivity of central neurons with increased sensitivity localized mainly in the CNS. Mast cells are involved in FM by releasing proinflammatory cytokines, chemokines, chemical mediators, and PGD2. TNF is a cytokine generated by MCs and its level is higher in FM. The inhibition of pro-inflammatory IL-1 family members and TNF by IL-37 in FM could have a therapeutic effect. Here, we report for the first time the relationship between MCs, inflammatory cytokines and the new anti-inflammatory cytokine IL-37 in FM.
Collapse
|